Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study

BMC Infectious Diseases

Carlo Luca Romanò¹  Roberto Mattina²  Nicola Logoluso¹  Christian Vassena⁴  Elena De Vecchi⁴  Delia Romanò¹  Lorenzo Drago³ 

[1] Department of Reconstructive Surgery of Osteo-articular Infections C.R.I.O. Unit, I.R.C.C.S. Galeazzi Orthopaedic Institute, Milan 20161, Italy;Department of Biomedical, Surgical and Odontoiatric Sciences, University of Milan, Via della Commenda 10, 20122, Milan, Italy;Department of Biomedical Sciences for Health, University of Milan, Via Mangiagalli 31, 20161, Milan, Italy;Laboratory of Clinical Chemistry and Microbiology, I.R.C.C.S. Galeazzi Orthopaedic Institute, Via R. Galeazzi 4, Milan 20161, Italy

关键词: Bioactive glass;    Pseudomonas aeruginosa;    Staphylococcus aureus;    Bone infections;   

Others  :  1145313
DOI  :  10.1186/1471-2334-13-584

 received in 2013-09-04, accepted in 2013-12-04,  发布年份 2013

【 摘 要 】

Background

This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis.

Methods

In vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic side effects connected with the BAG use.

Results

In vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after 24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed further surgical procedures. BAG-S53P4 was generally well tolerated.

Conclusions

The in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics.

Trial registration

Deutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332.

【 授权许可】

   
2013 Drago et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Romanò CL, Romanò D, Logoluso N, Drago L: Bone and joint infections in adults: a comprehensive classification proposal. Eur Orthop Traumatol 2011, 1:207-217.
• [2]Lew DP, Waldfogel FA: Osteomyelitis. Lancet 2004, 364:368-379.
• [3]Cierny G 3rd, Mader JT, Penninck JJ: A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res 2003, 414:7-24.
• [4]McPherson EJ, Woodson C, Holtom P, Roidis N, Shufelt C, Patzakis M: Periprosthetic total hip infection. Outcomes using a staging system. Clin Orthop Relat Res 2003, 403:8-15.
• [5]Parsson B, Strauss E: Surgical management of chronic osteomyelitis. Am J Surg 2004, 188:57-66.
• [6]Gordon L, Chiu EJ: Treatment of infected non-unions and segmental defects of the tibia with staged microvascular muscle transplantation and bone-grafting. J Bone Joint Surg Am 1988, 70:377-386.
• [7]Powerski M, Maier B, Frank J, Marzi I: Treatment of severe osteitis after elastic intramedullary nailing of a radial bone shaft fracture by using cancellous bone graft in Masquelet technique in a 13-year-old adolescent girl. J Pediatr Surg 2009, 44:17-19.
• [8]Calhoun JH, Anger DM, Mader JT: The Ilizarov technique in the treatment of osteomyelitis. Tex Med 1991, 87:56-59.
• [9]Ger R: Muscle transposition for treatment and prevention of chronic traumatic osteomyelitis of the tibia. J Bone Joint Surg Am 1977, 59:784-791.
• [10]Arkudas A, Balzer A, Buehrer G, Arnold I, Hoppe A, Detsch R, Newby P, Fey T, Greil P, Horch RE, Boccaccini AR, Kneser U: Evaluation of angiogenesis of bioactive glass in the arteriovenous loop model. Tissue Eng Part C Methods 2013, 19:479-486.
• [11]Day RM: Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro. Tissue Eng 2005, 11:768-777.
• [12]Hu S, Chang J, Liu M, Ning C: Study on antibacterial effect of 45S5 Bioglass. J Mater Sci Mater Med 2009, 20:281-286.
• [13]Leppäranta O, Vaahtio M, Peltola T, Zhang D, Hupa L, Hupa M, Ylänen H, Salonen JI, Viljanen MK, Eerola E: Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro. J Mater Sci Mater Med 2008, 19:547-551.
• [14]Lindfors NC, Hyvönen P, Nyyssönen M, Kirjavainen M, Kankare J, Gullichsen E, Salo J: Bioactive glass S53P4 as bone graft substitute in treatment of osteomyelitis. Bone 2010, 47:212-218.
• [15]Munukka E, Leppäranta O, Korkeamäki M, Vaahtio M, Peltola T, Zhang D, Hupa L, Ylänen H, Salonen JI, Viljanen MK, Eerola E: Bactericidal effects of bioactive glasses on clinically important aerobic bacteria. Mater Sci Mater Med 2008, 19:27-32.
• [16]Stoor P, Söderling E, Salonen JI: Antibacterial effects of a bioactive glass paste on oral microorganisms. Acta Odontol Scand 1998, 56:161-165.
• [17]Silvola JT: Mastoidectomy cavity obliteration with bioactive glass: a pilot study. Otolaryngol Head Neck Surg 2012, 147:119-126.
• [18]Sarin J, Grénman R, Aitasalo K, Pulkkinen J: Bioactive glass S53P4 in mastoid obliteration surgery for chronic otitis media and cerebrospinal fluid leakage. Ann Otol Rhinol Laryngol 2012, 121:563-569.
• [19]McAndrew J, Efrimescu C, Sheehan E, Niall D: Through the looking glass; bioactive glass S53P4 (BonAlive®) in the treatment of chronic osteomyelitis. Ir J Med Sci 2013, 182:509-511.
• [20]Monsen T, Lövgren E, Widerström M, Wallinder L: In vitro effect of ultrasound on bacteria and suggested protocol for sonication and diagnosis of prosthetic infections. J Clin Microbiol 2009, 47:2496-2501.
• [21]Jonasson J, Olofsson M, Monstein HJ: Classification, identification and subtyping of bacteria based on pyrosequencing and signature matching of 16 s rDNA fragments. APMIS 2007, 15:668-677.
• [22]Hum J, Boccaccini AR: Bioactive glasses as carriers for bioactive molecules and therapeutic drugs: a review. J Mater Sci Mater Med 2012, 23:2317-2333.
• [23]Geurts J, Chris Arts JJ, Walenkamp GH: Bone graft substitutes in active or suspected infection. Contra-indicated or not? Injury 2011, 42(Suppl 2):82-86.
• [24]Jones JR: Review of bioactive glass: from Hench to hybrids. Acta Biomater 2013, 9:4457-4486.
• [25]Hench LL, Paschall HA: Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. Biomed Mater Res 1973, 7:25-42.
• [26]Cormack AN, Tilocca A: Structure and biological activity of glasses and ceramics. Philos Trans A Math Phys Eng Sci 2012, 370:1271-1280.
• [27]Stoor P, Pulkkinen J, Grénman R: Bioactive glass S53P4 in the filling of cavities in the mastoid cell area in surgery for chronic otitis media. Ann Otol Rhinol Laryngol 2010, 119:377-382.
• [28]Andersson OH, Rosenqvist J, Karlsson KH: Dissolution, leaching, and Al2O3 enrichment at the surface of bioactive glasses studied by solution analysis. J Biomed Mater Res 1993, 27:941-948.
• [29]Ballo AM, Lassila LV, Vallittu PK, Närhi TO: Load bearing capacity of bone anchored fiber-reinforced composite device. J Mater Sci Mater Med 2007, 18:2025-2031.
• [30]Virolainen P, Heikkilä J, Yli-Urpo A, Vuorio E, Aro HT: Histomorphometric and molecular biologic comparison of bioactive glass granules and autogenous bone grafts in augmentation of bone defect healing. J Biomed Mater Res 1997, 35:9-17.
• [31]Peltola M, Aitasalo K, Suonpää J, Varpula M, Yli-Urpo A: Bioactive glass S53P4 in frontal sinus obliteration: a long-term clinical experience. Head Neck 2006, 28:834-841.
• [32]Frantzén J, Rantakokko J, Aro HT, Heinänen J, Kajander S, Gullichsen E, Kotilainen E, Lindfors NC: Instrumented spondylodesis in degenerative spondylolisthesis with bioactive glass and autologous bone: a prospective 11-year follow-up. J Spinal Disord Tech 2011, 24:455-461.
• [33]Lindfors NC, Koski I, Heikkilä JT, Mattila K, Aho AJ: A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res B Appl Biomater 2010, 94:157-164.
• [34]Pernaa K, Koski I, Mattila K, Gullichsen E, Heikkila J, Aho A, Lindfors N: Bioactive glass S53P4 and autograft bone in treatment of depressed tibial plateau fractures - a prospective randomized 11-year follow-up. J Long Term Eff Med Implants 2011, 21:139-148.